Thus, in the current study we aimed to investigate the VISTA expression and its relationship with CD8+TILs, as a significant effector of adaptative immunity, with the Natural Killer (NK) as an effector of innate immunity and clinical outcomes in ovarian carcinoma, to understand the role and status of this novel checkpoint in ovarian carcinoma microenvironment and to check whether its targeting enhances anti-tumor response for EOC immunotherapy. Here, CD8A is linked to ovarian carcinoma.